The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks. Cutaneous squamous cell carcinoma (cSCC) is the second most common ...

BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted ...

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma ...

Checkpoint Therapeutics (CKPT) announced that the U.S. FDA has approved unloxcyt for the treatment of adults with metastatic cutaneous squamous ...

The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics' drug for treatment of a type of ...

BioNTech (BNTX) said it has been informed by its partner OncoC4 that the Food and Drug Administration has lifted the partial clinical hold on ...

ESPN analyst Randy Moss, who retired from the NFL in 2012 after 14 seasons, revealed that he is a “cancer survivor” and will ...

Shares of Checkpoint Therapeutics rose 4.6% to $3.84 in post-market trading after the Food and Drug Administration approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Checkpoint Therapeutics said the Food and Drug Administration approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, the company's first approval. Checkpoint said in July ...